First authors of the article -Jeff Weitz/Hamilton Health Sciences; Robert Harrington/Weill Cornell Medicine
May 2, 2026, 13:10
Targeting FXIa As a Safer Anticoagulant Target Than FXa in LIBREXIA Trial – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by et al, adding:
”Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
This narrative review details the pharmacological rationale for targeting FXIa as a safer anticoagulant target than FXa, and outlines how phase 2 findings informed milvexian dosing regimens across three phase 3 LIBREXIA trials enrolling approximately 50,000 patients with AF, ACS, or ischemic stroke.”
Title: Rationale for the Milvexian Dosing in the Phase 3 LIBREXIA Program
Authors: Jeff Weitz, Robert Harrington on behalf of the LIBREXIA Program Executive Council
Stay updated on all scientific advances with Hemostasis Today.
-
Sep 14, 2026, 07:54Islam Sadek: SOHO2026 Highlights Advances in Hematologic Malignancies
-
Sep 14, 2026, 07:45Flora Peyvandi: Building a More Equitable Future for Hemophilia Care
-
Sep 14, 2026, 07:37Joseph Pierre Aboumsallem: ET Treatment Enters a New Chapter
-
Sep 14, 2026, 07:29Eric Topol – Will AI Replace Clinicians?
-
Sep 14, 2026, 07:19Ruhi Mehra: The Evolving Science of Stem Cell Enumeration
-
Sep 14, 2026, 07:05Don’t Overlook Superficial Clots – World Thrombosis Day
-
Sep 14, 2026, 06:55Transforming Hemophilia A Treatment with Bispecific Antibodies – NEJM Group
-
Sep 14, 2026, 06:51Alexander Hof: Species-Specific Roles of MPO Deficiency
-
Sep 14, 2026, 06:36Patrick Badertscher: PVI With vs Without Posterior Wall Isolation in Persistent AF